Welcome to LookChem.com Sign In|Join Free

CAS

  • or

90323-97-0

Post Buying Request

90323-97-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

90323-97-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 90323-97-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,3,2 and 3 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 90323-97:
(7*9)+(6*0)+(5*3)+(4*2)+(3*3)+(2*9)+(1*7)=120
120 % 10 = 0
So 90323-97-0 is a valid CAS Registry Number.

90323-97-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 1,2-dimethyl-5,6-dinitrobenzimidazole

1.2 Other means of identification

Product number -
Other names 1H-Benzimidazole,1,2-dimethyl-5,6-dinitro

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:90323-97-0 SDS

90323-97-0Relevant articles and documents

Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit

Gazit, Aviv,Yee, Kevin,Uecker, Andrea,Boehmer, Frank-D.,Sjoeblom, Tobias,Oestman, Arne,Waltenberger, Johannes,Golomb, Gershon,Banai, Shmuel,Heinrich, Michael C.,Levitzki, Alexander

, p. 2007 - 2018 (2007/10/03)

Here we report on novel quinoxalines as highly potent and selective inhibitors of the type III receptor tyrosine kinases PDGFR, FLT3, and KIT. These compounds, tricyclic quinoxalines, were generated in order to improve bioavailability over the highly hydrophobic bicyclic quinoxalines. Four of the highly active compounds were characterized in detail and are shown to inhibit PDGFR kinase activity of the isolated receptor as well as in intact cells in the sub-micromolar concentration range. We show that the most active inhibitor (compound 13, AGL 2043) is ~15-20 times more potent than its isomer (compound 14, AGL 2044). We therefore compared the three dimensional structures of the two compounds by X-ray crystallography. These compounds are also highly effective in blocking the kinase activity of FLT3, KIT, and the oncogenic protein Tel-PDGFR in intact cells. These compounds are potent inhibitors of the proliferation of pig heart smooth muscle cells. They fully arrest the growth of these cells and the effect is fully reversible. The chemical, biochemical and cellular properties of these compounds as well as the solubility properties make them suitable for development as anti-restenosis and anti-cancer agents.

Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors

-

, (2008/06/13)

The present invention relates to tricyclic quinoxaline compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein tyrosine kinases and therefore should be useful in the prevention and treatment of protein ty

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 90323-97-0